Merck & Co. Inc. (MRK): Price and Financial Metrics


Merck & Co. Inc. (MRK): $76.95

-1.38 (-1.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MRK POWR Grades


  • MRK scores best on the Stability dimension, with a Stability rank ahead of 91.39% of US stocks.
  • MRK's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • MRK ranks lowest in Momentum; there it ranks in the 11th percentile.

MRK Stock Summary

  • Merck & Co Inc's market capitalization of $198,336,131,652 is ahead of 98.93% of US-listed equities.
  • Merck & Co Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.76% of US equities in our set.
  • The volatility of Merck & Co Inc's share price is greater than that of merely 0.56% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MRK, based on their financial statements, market capitalization, and price volatility, are CVX, NVS, TMO, COST, and T.
  • MRK's SEC filings can be seen here. And to visit Merck & Co Inc's official web site, go to www.merck.com.

MRK Valuation Summary

  • In comparison to the median Healthcare stock, MRK's price/sales ratio is 13.89% higher, now standing at 4.1.
  • Over the past 243 months, MRK's price/sales ratio has gone up 0.6.
  • Over the past 243 months, MRK's EV/EBIT ratio has gone up 10.6.

Below are key valuation metrics over time for MRK.

Stock Date P/S P/B P/E EV/EBIT
MRK 2019-01-16 4.6 6.0 58.0 26.4
MRK 2018-08-17 4.5 5.6 137.0 36.8
MRK 2011-07-19 2.4 2.0 68.8 44.0
MRK 2006-09-19 4.0 4.6 16.1 11.6
MRK 2006-08-23 3.9 4.6 15.8 11.4
MRK 2005-10-12 2.7 3.4 13.0 9.1

MRK Growth Metrics

  • The year over year cash and equivalents growth rate now stands at -5.98%.
  • The 5 year net cashflow from operations growth rate now stands at 82.75%.
  • Its 4 year cash and equivalents growth rate is now at -23.58%.
Over the past 34 months, MRK's revenue has gone up $6,758,000,000.

The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 48,018 11,337 7,028
2020-12-31 47,994 10,253 7,067
2020-09-30 47,348 11,041 11,518
2020-06-30 47,194 13,094 10,478
2020-03-31 48,082 12,811 10,146
2019-12-31 46,840 13,440 9,843

MRK Price Target

For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $93.02 Average Broker Recommendation 1.54 (Moderate Buy)

MRK Stock Price Chart Interactive Chart >

Price chart for MRK

MRK Price/Volume Stats

Current price $76.95 52-week high $87.80
Prev. close $78.33 52-week low $71.71
Day low $76.83 Volume 6,625,905
Day high $77.92 Avg. volume 11,663,556
50-day MA $76.84 Dividend yield 3.32%
200-day MA $77.95 Market Cap 194.84B

Merck & Co. Inc. (MRK) Company Bio


Merck & Co., Inc.d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)


MRK Latest News Stream


Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream


Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about Merck & Co Inc that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer

ALX Oncology Holdings (ALXO) in partnership with Merck (MRK) announce the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with Keytruda (pembrolizumab), an anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and...

Seeking Alpha | July 28, 2021

Covid-19 vaccine booster shots will become a reality: Doctor

Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | July 28, 2021

Ripple effects of the CDC indoor mask guidance

Yahoo Finance’s Alexis Keenan reports details on the CDC’s reversal in mask guidance fro vaccinated Americans and Google’s mandate on vaccinations.

Yahoo | July 28, 2021

Merck Recognized on Best Places to Work for Disability Inclusion List and Received Perfect Score on the Disability Equality Index (DEI)

For the seventh year in a row, Merck has been recognized on the Best Places to Work for Disability Inclusion list — and for the fourth straight year, Merck has received a score of 100% on the Disab...

Yahoo | July 28, 2021

‘There’s a great opportunity that we’ll have another variant’: Doctor

Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

Yahoo | July 27, 2021

Read More 'MRK' Stories Here

MRK Price Returns

1-mo -0.34%
3-mo 4.18%
6-mo 1.59%
1-year 0.17%
3-year 29.81%
5-year 52.53%
YTD -4.29%
2020 -7.20%
2019 22.27%
2018 39.95%
2017 -1.49%
2016 15.05%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8453 seconds.